Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma ; volume:22 ; number:1 ; day:12 ; month:10 ; year:2022 ; pages:1-14 ; date:12.2022
Cancer cell international ; 22, Heft 1 (12.10.2022), 1-14, 12.2022
- Creator
-
Kang, Junwei
Zheng, Zhiying
Li, Xian
Huang, Tian
Rong, Dawei
Liu, Xinyang
Qin, Miaomiao
Wang, Yuliang
Kong, Xiangyi
Song, Jinhua
Lv, Chengyu
Pan, Xiongxiong
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-022-02735-3
- URN
-
urn:nbn:de:101:1-2022122920591966809977
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kang, Junwei
- Zheng, Zhiying
- Li, Xian
- Huang, Tian
- Rong, Dawei
- Liu, Xinyang
- Qin, Miaomiao
- Wang, Yuliang
- Kong, Xiangyi
- Song, Jinhua
- Lv, Chengyu
- Pan, Xiongxiong
- SpringerLink (Online service)
Other Objects (12)
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
A 90Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
Exhibits
Exhibits
Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy
Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
A 90Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
Exhibits
Exhibits
Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy
Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
A 90Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
Exhibits
Exhibits
Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy
Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy